pyridostigmine bromide has been researched along with hydroxyproline in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bi, XY; Kong, SS; Liu, JJ; Lu, Y; Qin, FF; Yu, XJ; Zang, WJ; Zhou, J | 1 |
1 other study(ies) available for pyridostigmine bromide and hydroxyproline
| Article | Year |
|---|---|
Pyridostigmine ameliorates cardiac remodeling induced by myocardial infarction via inhibition of the transforming growth factor-β1/TGF-β1-activated kinase pathway.
Topics: Animals; Cholinesterase Inhibitors; Fibrosis; Hemodynamics; Hydroxyproline; Male; MAP Kinase Kinase Kinases; Matrix Metalloproteinase 2; Myocardial Infarction; Pyridostigmine Bromide; Rats; Rats, Sprague-Dawley; Signal Transduction; Transforming Growth Factor beta1; Ventricular Remodeling | 2014 |